Immunotherapy Rechallenge in Patients with Solid Tumors in Clinical Trials

NCT06612632 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Cancer

Interventions

DRUG: research drug in combination with Toripalimab
DRUG: Toripalimab

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences